Top Reasons to Buy this Companion Diagnostics and Biomarker Development Report
Create an Effective Strategic Plan: See how other companies approach companion diagnostics, learning how they analyze the different factors that impact their go/no-go decisions and select the actual tests. The report also explores what is done in-house versus handled at diagnostics companies as you peruse real-company staffing data and budget ranges from across the life sciences.
Align Drug and Diagnostic Regulatory Timelines: Running a clinical trial in and of itself is hard; adding a diagnostic’s development at the same time is even more challenging, but essential. See detailed timeline breakdowns by development stage to keep products on track.
Master Partner Selection, Coordination, and Partnership Management: The right partner can mean the difference between lucrative results and disappointing outcomes. Learn who’s involved in partner selection — and the six (6) critical factors companies consider — and who leads the partnership at different points in product development. The report also identifies red flags foreshadowing potential partnership problems and includes best practices for strengthening communication between both sides. Along the way, discover how some companies rate six major diagnostics firms on specific tests.
Track Therapeutic Area Data: Get a firm handle on companion diagnostics activity in five prominent therapeutic areas (oncology, CNS, cardiovascular, inflammation and virology). Each snapshot shows the percentage of the company’s pipeline with a biomarker/CDx program, type of program, and program goals.
Key Questions Answered About Companion Diagnostics and Biomarker Development
- How do other companies approach diagnostics?
- What factors do teams consider?
- What happens in-house?
- It’s hard enough running a drug trial — what happens when a companion diagnostic’s involved?
- How much does this cost? How big are the teams?
- How does partner selection work? Who’s involved? How do you uncover partner capabilities?
- How does development differ in different therapeutic areas?
- How prominent are diagnostics in different therapeutic areas?
|Publication Date||February 2012|
|Chapters||3 + Appendix|
|Charts / Graphics||90 +|